Biosimilars Pathway: A Far Cry From Hatch-Waxman

Law360, New York (March 30, 2010, 2:24 PM EDT) -- On March 23, 2010, President Obama signed into law Pub. Law. No. 111-148, the APPROVAL PATHWAY FOR BIOSIMILAR BIOLOGICAL PRODUCTS (i.e., Biosimilars Pathway), a component of the Patient Protection and Affordable Care Act. This legislation creates, for the first time, a pathway for the production, use and sale of follow-on biologic therapeutics in the United States.

The U.S. is now among many countries in the world having a pathway for biosimilar products, including those in the EU that, in 2004, adopted biosimilars legislation and subsequently approved...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.